Melanie Saunders is urging people not to take their health for granted after having to drop out of nursing school due to her ...

Ocular Rosacea: Developing a gel formulation of Xdemvy, aiming to reduce eyelid redness and inflammation. Lyme Disease: An oral prophylactic with a 98% tick kill rate within 24 hours, considering ...

LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- The blepharitis market has seen rapid growth in recent years. The market size is forecasted to grow from $0.86 billion in ...

TARS can expand lotilaner beyond Demodex blepharitis, with trials set to initiate in H2'25 in ocular rosacea and 2026 for Lyme disease prevention.

Eye mites are also more common in people who wear contact lenses and people with rosacea, blepharitis or diabetes. Diagnosis and treatment ...

XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular ...

On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to host conference call today, May 1, 2025, at 1:30 p.m ...

Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the prevention of Lyme disease, all of which are in Phase 2. Forward-Looking Statements ...

XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the ...

A Phase II study for ocular rosacea is set to begin in late 2025, with data expected in 2026. Tarsus aims to expand physician education to identify Demodex blepharitis in broader patient categories.

XDEMVY continued to be one of the fastest growing therapeutics in eye care. Generated $66.4 million and $180.1 million in XDEMVY net product sales for the fourth quarter and full-year 2024 ...